Welcome to our dedicated page for INSMED SEC filings (Ticker: INSM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Insmed Incorporated filings document formal disclosures for its commercial biopharmaceutical portfolio and respiratory and inflammatory pipeline. Recent Form 8-K reports furnish financial results, investor presentations, Regulation FD materials, clinical-study updates for ARIKAYCE and brensocatib, regulatory approval announcements for BRINSUPRI, and portfolio additions such as INS1148.
The company’s proxy materials describe board elections, executive compensation, equity awards, shareholder voting matters and governance practices. Other current reports document compensatory arrangements, director-transition disclosures, exhibits and Inline XBRL cover-page data tied to Insmed’s Nasdaq-listed common stock.
INSMED Inc Chair and CEO William Lewis reported an open-market sale of 6,515 shares of Common Stock. The shares were sold at a price of $94.03 per share. After this transaction, he directly holds 258,917 shares of Common Stock.
The filing also shows an indirect holding of 233,924 shares of Common Stock held by a trust. According to a footnote, the sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 4, 2025, indicating it was scheduled in advance.
INSM reported a Form 144 notice reporting proposed sales of Common Stock by William Lewis. The filing lists multiple proposed sale dates and quantities, including 7,605 shares on 06/03/2026 and 25,564 shares on 05/18/2026. The entries show share counts tied to each sale row and resulting share figures on the same lines.
INSM reported officer stock sale transactions under Rule 144. The filing lists recent dispositions of Common Stock executed through Merrill Lynch on 06/01/2026 and shows multiple seller entries for Martina Flammer. Examples include sales on 06/03/2026 (2,566 shares), 05/14/2026 (10,479 shares) and 05/13/2026 (7,854 shares). The submission uses a broker-dealer address in Washington, D.C., and is recorded on 06/05/2026.
INSMED Inc Chief Operating Officer Roger Adsett reported a sale of 2,370 shares of common stock. The shares were sold at an average price of $102.27 per share to satisfy tax withholding obligations related to the vesting of Restricted Stock Units and to cover associated broker fees. After this transaction, Adsett directly holds 98,603 shares of INSMED common stock, indicating this was a routine, tax-driven disposition rather than a discretionary reduction in his equity stake.
Insmed Inc.’s Chief Financial Officer Sara Bonstein reported an automatic sale of shares tied to equity compensation. On the reported date, 2,404 shares of common stock were sold at $102.27 per share. According to the footnote, the shares were sold to satisfy tax withholding obligations when Restricted Stock Units vested and to cover related broker fees, rather than as a discretionary portfolio move. After this transaction, Bonstein directly owned 69,082 Insmed shares, so the filing mainly reflects routine tax handling on stock-based compensation.
INSMED Inc Chief Legal Officer Michael Alexander Smith reported an open-market sale of company stock mainly to cover taxes on vesting equity.
He sold 2,159 shares of Common Stock at $102.27 per share to satisfy tax withholding obligations from vested Restricted Stock Units and related broker fees. After this transaction, he directly holds 39,454 shares, so the sale represents only a portion of his overall stake and is characterized as a tax-related, administrative transaction rather than a discretionary reduction in ownership.
INSMED Inc Chair and CEO William Lewis reported an insider transaction involving company common stock. On June 3, 2026, he sold 7,605 shares of common stock at $102.27 per share. According to the footnote, these shares were sold to satisfy tax withholding obligations upon the vesting of Restricted Stock Units and to cover related broker fees, meaning this was a tax-related sale rather than a discretionary trade. Following the transaction, Lewis held 265,432 shares directly and 233,924 shares indirectly through a trust.
Insmed Inc.’s Chief Medical Officer, Dr. Martina Flammer, reported two small open-market sales of common stock made to cover taxes on equity compensation. She sold 2,566 shares at $102.27 on June 3 and 1,858 shares at $103.78 on June 5, totaling 4,424 shares. After these transactions, she directly holds 60,486 shares of Insmed common stock. The footnotes state the shares were sold to satisfy tax withholding obligations upon the vesting of Restricted Stock Units and related broker fees, and that the trades were executed under a pre-arranged Rule 10b5-1 trading plan adopted on February 27, 2025.
INSM reported proposed sales of Common Stock under a Form 144 notice. The filing lists securities to be sold tied to stock plan activity dated 06/01/2026 and a separate reported sale of 8,272 shares on 05/13/2026 by Sara Bonstein.
INSM reported proposed sales of common stock by an insider via Form 144. The filing lists three proposed dispositions by Martina Flammer on 05/11/2026, 05/13/2026, and 05/14/2026, with the reported share amounts shown for each date.
The entries show 12,949 shares on 05/11/2026, 7,854 shares on 05/13/2026, and 10,479 shares on 05/14/2026, alongside the related beneficial ownership figures provided on each row.